NOVAVAX INC
Company Stats
- Market Cap
- $1.8B
- as of Sep 30, 2026
- Shares Outstanding
- 164.9M
- Free Float
- 78.0%
Income Statement
- Revenue
- $1.1B
- Operating Income
- $452.8M
- Net Income
- $440.3M
- EBITDA
- $480.8M
- Revenue Growth, 3Y
- -17.2%
- FCF Margin, 3Y Avg
- -36.0%
- FCF Margin, Worst Year
- -73.4%
Cash Flow
- Free Cash Flow
- -$244.6M
- FCF Yield
- -13.7%
- Owner FCF Yield
- -15.7%
Balance Sheet
- Cash & Equivalents
- $240.6M
Returns & Capital
- SBC, 3Y Avg
- $56.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $1.1B | -$244.6M | -21.8% |
| FY2024 | $682.2M | -$88.3M | -12.9% |
| FY2023 | $983.7M | -$721.9M | -73.4% |
| FY2022 | $2.0B | -$433.6M | -21.9% |
| FY2021 | $1.1B | $265.5M | 23.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 9, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges